FRCA Notes


Glycaemic Control in Critical Care


  • Hyperglycaemia is common in the critically ill, whether or not patients have diabetes ('stress hyperglycaemia')
  • It results from counter-regulatory hormones, inflammatory cytokines, insulin resistance and treatments such as steroids, catecholamines and parenteral nutrition (see diabetes physiology)

  • Hyperglycaemia is associated with:
    • Pro-inflammatory and prothrombotic effects
    • Impaired immune function and increased infection
    • Increased mortality across many cohorts e.g. trauma, TBI, SAH, MI, sepsis, stroke

  • Hypoglycaemia and glycaemic variability are also independently associated with mortality
  • Moderate control with an upper limit of ~10mmol/L is now standard, avoiding both tight control and permissive hyperglycaemia

Leuven I and II (2001 and 2006)

  • Single-centre trials of intensive insulin therapy (target 4.4-6.1mmol/L) vs. conventional control
  • In surgical ICU patients (Leuven I), tight control reduced mortality by 34%, as well as sepsis, critical illness polyneuropathy and renal failure
  • Leuven II did not replicate these results in medical ICU patients
  • Patients received early intravenous glucose and parenteral nutrition, which limits generalisability

VISEP (2008)

  • Intensive insulin therapy in severe sepsis did not affect organ failure or mortality
  • Increased severe hypoglycaemia and serious adverse events

NICE-SUGAR (2009)

  • Multicentre RCT of tight (4.5-6.0mmol/L) vs. conventional (<10mmol/L) control in over 6000 patients
  • Tight control increased 90-day mortality (absolute increase 2.6%)
  • Severe hypoglycaemia was ~13 times more common, and was itself associated with death, particularly in distributive shock

CONTROLING (2021)

  • Individualised targets based on the patient's pre-admission HbA1c vs. standard (<10mmol/L) control
  • No survival benefit at 90 days, and a signal towards harm; stopped early
  • Tight (4.4-6.1mmol/L) vs. liberal control in over 9000 patients, with early parenteral nutrition withheld
  • No difference in duration of ICU dependency or 90-day mortality
  • Suggests the benefit seen in Leuven I was linked to the hyperglycaemia caused by early parenteral feeding

Surviving Sepsis Campaign (2021)

  • Start insulin when blood glucose is ≥10mmol/L (180mg/dl)
  • Then target 8-10mmol/L
  • Use a protocolised approach

International recommendations for glucose control in non-diabetic critically ill adults (2010)

  • Aim <10mmol/L (7.8-10mmol/L acceptable)
  • Avoid severe hypoglycaemia (<2.2mmol/L)
  • Use arterial rather than capillary samples, analysed on a blood gas or laboratory analyser rather than a point-of-care meter

Patients with diabetes

  • Patients with chronic hyperglycaemia may tolerate higher glucose and be more vulnerable to 'relative hypoglycaemia', but individualised higher targets are not yet supported by trial evidence

Measurement

  • Capillary glucose meters are unreliable in shock, hypoperfusion, oedema and vasopressor use, and are affected by haematocrit and PO2 (see glucose and ketone meters)
  • Arterial blood analysed on a blood gas analyser is preferred
  • Measure 1-2 hourly while on insulin, and more frequently after changes or when values are falling

Insulin

  • Intravenous insulin infusion by protocol, as subcutaneous absorption is unpredictable
  • Provide a carbohydrate source (feed or glucose) whenever insulin is running, and reduce or stop insulin if feeding is interrupted
  • Monitor potassium, magnesium and phosphate, which fall with insulin
  • Patients with type 1 diabetes must always have some insulin, even if glucose is normal

Non-insulin diabetes medicines

  • Most are withheld in the critically ill:
    • Metformin: risk of lactic acidosis with hypoperfusion and AKI
    • Sulphonylureas: hypoglycaemia with impaired absorption and clearance
    • SGLT2 inhibitors: euglycaemic DKA and volume depletion; monitor ketones
    • GLP-1 receptor agonists: GI effects and unpredictable absorption; long half-lives mean effects persist after stopping

Hypoglycaemia

  • Risk factors: tight targets, sepsis, renal and hepatic failure, interruption of feed, renal replacement therapy, insulin errors
  • Signs are masked by sedation, so detection relies on regular measurement
  • Treat promptly with intravenous glucose and review the cause